---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-425243"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2026-10-19T20:11:18+00:00"
generated_at: "2026-10-19T20:12:06.824402+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics promotes Andrew Silver to CFO as Raju Prasad resigns

## Summary
- Andrew J. Silver, 42, was promoted to Chief Financial Officer effective October 19, 2026; he will serve as principal financial and accounting officer.
- Silver's annual salary is $515,000 with a 45% target bonus and a one-time grant of 25,000 restricted stock units vesting on the second anniversary.
- Raju Prasad, Ph.D. resigned as CFO to pursue external opportunities; CRISPR said the resignation was not due to any disagreement and he is expected to stay until on or before November 30, 2026.
- The employment agreement provides six months' notice for involuntary departure, or 12 months plus equity acceleration within 12 months after a Change in Control.

## SEC filing metadata
- accession: 0001193125-26-425243
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2026-10-19T20:11:18+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000119312526425243/0001193125-26-425243-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000119312526425243/crsp-20261019.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-425243
- JSON: https://secwatch.observer/filing/0001193125-26-425243.json
- Plain text: https://secwatch.observer/filing/0001193125-26-425243.txt

## Key facts
- Executive change
  Andrew J. Silver changed role as Chief Financial Officer at CRISPR Therapeutics AG.
  - Action: promoted
  - Role: Chief Financial Officer
  source text: On October 19, 2026, CRISPR Therapeutics AG (the “Company”) announced the promotion of Andrew J. Silver, currently the Company’s SVP, Finance, to be the Company’s Chief Financial Officer effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674416/000119312526425243/0001193125-26-425243-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.